New ReFRAME drug repurposing collection offers hope for treating major diseases
Share you research at the Euro Medicinal Chemistry meet and get your article published in related reputed journals.
For more details, kindly visit: Medicinal Chemistry Conferences
The
Calibr scientists are using this collection, called ReFRAME, to identify
existing drugs that show promise for treating major diseases. Because of this
ReFRAME initiative, two FDA-approved drugs are already being tested in clinical
trials--one as a treatment for tuberculosis and another for the
parasite Cryptosporidium spp., a major cause of severe
diarrhea--within only a few short years of Calibr scientists discovering their
utility. This contrasts with the much longer timelines that often hinder new drug
development.
To
construct ReFRAME, Calibr researchers gathered data on more than 12,000
small-molecule drugs by combining three widely-used commercial drug databases
(Clarivate Integrity, GVK Excelra GoStar and Citeline Pharmaprojects), which
are typically used by pharmaceutical and biotech companies to assess
competition and guide drug research and development.
"ReFRAME
was developed as a singular new resource for the global health drug discovery
community and is the largest and most comprehensive repurposing collection
available," says Arnab Chatterjee, PhD, vice president of medicinal
chemistry at Calibr and lead researcher on the project. "In addition to
consolidating compounds from multiple existing collections, we synthesized
around 5,000 molecules that are not commercially available--from which we
identified the two new hits against Cryptosporidium."
In
their study, the Calibr scientists placed the parasites in thousands of small
chambers and dosed them with samples of the drugs to determine which compounds
killed them. Drugs that killed Cryptosporidium in the chambers were
then given to mice infected with the parasite, and two drugs, VB-201(CI-201)
and ASP-7962, proved effective at treating the infections in the animals. The
researchers were able to move from identifying the compounds to animal studies
in about two months, a remarkably rapid advance from one phase of drug
discovery research to another.
"These
two compounds show promise for providing therapeutics for targeting the
parasite and not just the symptoms," says Case McNamara, PhD, a principal
investigator at Calibr and coauthor on the paper. "If they prove effective
at treating this disease in humans, it could impact the lives of millions of
people worldwide."
Source: NEWS Medical Lifesciences
No comments:
Post a Comment